Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Jolanda Howe Sells 902 Shares

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Jolanda Howe sold 902 shares of the firm’s stock in a transaction that occurred on Friday, January 24th. The shares were sold at an average price of $47.92, for a total value of $43,223.84. Following the completion of the sale, the senior vice president now directly owns 3,524 shares of the company’s stock, valued at $168,870.08. This represents a 20.38 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Jolanda Howe also recently made the following trade(s):

• On Tuesday, January 7th, Jolanda Howe sold 750 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $42.82, for a total value of $32,115.00.
• On Thursday, November 14th, Jolanda Howe sold 2,500 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $47.10, for a total transaction of $117,750.00.

Mirum Pharmaceuticals Stock Performance

NASDAQ MIRM opened at $48.60 on Thursday. The company has a quick ratio of 3.15, a current ratio of 3.34 and a debt-to-equity ratio of 1.33. Mirum Pharmaceuticals, Inc. has a fifty-two week low of $23.14 and a fifty-two week high of $49.58. The business has a fifty day moving average of $44.03 and a 200-day moving average of $41.75. The stock has a market cap of $2.33 billion, a price-to-earnings ratio of -24.06 and a beta of 0.98.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its earnings results on Tuesday, November 12th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.15. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. The firm had revenue of $90.38 million during the quarter, compared to the consensus estimate of $81.99 million. During the same quarter in the previous year, the company posted ($0.57) EPS. The firm’s revenue for the quarter was up 89.4% on a year-over-year basis. As a group, analysts predict that Mirum Pharmaceuticals, Inc. will post -1.45 earnings per share for the current fiscal year.

Institutional Trading of Mirum Pharmaceuticals

A number of hedge funds have recently bought and sold shares of MIRM. Lord Abbett & CO. LLC purchased a new stake in shares of Mirum Pharmaceuticals in the third quarter valued at $28,913,000. Loomis Sayles & Co. L P purchased a new stake in Mirum Pharmaceuticals in the 3rd quarter valued at about $19,473,000. Clearbridge Investments LLC increased its stake in shares of Mirum Pharmaceuticals by 165.5% during the 2nd quarter. Clearbridge Investments LLC now owns 699,933 shares of the company’s stock valued at $23,931,000 after acquiring an additional 436,349 shares during the last quarter. State Street Corp lifted its holdings in shares of Mirum Pharmaceuticals by 19.9% during the 3rd quarter. State Street Corp now owns 1,793,728 shares of the company’s stock worth $69,955,000 after acquiring an additional 297,511 shares during the period. Finally, Erste Asset Management GmbH acquired a new stake in shares of Mirum Pharmaceuticals in the third quarter worth approximately $10,136,000.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the stock. Leerink Partners raised their price objective on shares of Mirum Pharmaceuticals from $47.00 to $49.00 and gave the company an “outperform” rating in a research note on Thursday, October 17th. Citigroup boosted their price target on Mirum Pharmaceuticals from $65.00 to $68.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. HC Wainwright reaffirmed a “buy” rating and issued a $66.00 price objective on shares of Mirum Pharmaceuticals in a research note on Wednesday, November 13th. Finally, Robert W. Baird boosted their target price on Mirum Pharmaceuticals from $44.00 to $50.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 13th. Ten research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $57.10.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.